Related Experiment Video

Updated: May 1, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.3K

[Cardiovascular effects and safety of glucose-lowering drugs: current situation]

L Masmiquel1

  • 1Servicio de Endocrinología, Hospital Son Llàtzer, Palma de Mallorca, España.

Semergen
|March 25, 2014
PubMed

Insights

Diabetes mellitus increases cardiovascular risk. This review examines glucose-lowering drugs, evaluating their cardiovascular safety and impact on major cardiovascular events to guide treatment decisions.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Context:

  • Diabetes mellitus is a significant independent risk factor for cardiovascular disease.
  • Current treatment guidelines emphasize blood glucose normalization but require better evidence on cardiovascular protection.
  • Regulatory agencies now mandate robust cardiovascular safety assessments for new glucose-lowering drug approvals.

Purpose:

  • To review the cardiovascular effects of various glucose-lowering drugs.
  • To analyze the impact of these agents on the risk of major cardiovascular events.
  • To provide evidence-based insights for clinical practice and drug development.

Summary:

  • Evidence on the cardiovascular protective role of glucose-lowering drugs is limited, especially concerning major adverse cardiovascular events.
  • New drug approvals require demonstration of both glucose-lowering efficacy and cardiovascular safety.
  • This review synthesizes current knowledge on the cardiovascular impact of different glucose-lowering medications.

Impact:

  • Inform clinical decision-making regarding the selection of glucose-lowering therapies in diabetic patients.
  • Guide pharmaceutical research and development towards agents with favorable cardiovascular profiles.
  • Contribute to updated guidelines for diabetes management, prioritizing cardiovascular risk reduction.
Keywords:
Anti-diabeticsAntidiabéticosCardiovascular riskDiabetes mellitusEventos cardiovasculares mayoresGlucose-lowering drugsHipoglucemiantesMajor cardiovascular eventsRiesgo cardiovascular

More Related Videos

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo10:35

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo

Published on: April 6, 2022

2.7K
Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.7K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
953
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
4.3K
Overview of Carbohydrate Metabolism01:19

Overview of Carbohydrate Metabolism

Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
4.5K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K